Delivery Order SPE2DB24D2205-SPE2DB25FDZXA

Award Date 3/20/25
Potential Completion Date 3/21/25
Potential Value $2.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of NAYZILAM 5 MG NASAL SPRAYS. The contract is a firm fixed-price delivery order with a ceiling value of $1,974.49 and a period of performance through February 26, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 through November 2026, which...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,074.81, is for the delivery of NAYZILAM 5 MG NASAL SPRAYS. It is a firm-fixed-price contract with a period of performance through February 12, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,424.41 firm fixed-price delivery order is for the supply of NAYZILAM 5 MG NASAL SPRAYS, with a performance period ending on March 17, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distribution company, for the supply of NAYZILAM 5 MG NASAL SPRAYS. The award has a ceiling value of $2,725.00 and an ultimate completion date of December 2, 2024. The contract is a Firm Fixed Price (FFP) delivery order, with no set-aside designation. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at...
This is a $1,061.13 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of NAYZILAM 5 MG NASAL SPRAYS. The contract has an ultimate completion date of August 1, 2024 and does not have a set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued up to $999,999,999 through December 2025 for delivering a wide...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $1,994.99 firm fixed-price delivery order is for the supply of NAYZILAM 5 MG NASAL SPRAYS, a medication, with a performance period through March 4, 2025. The contract is not designated as a set-aside. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of NAYZILAM 5 MG NASAL SPRAYS. The contract has a ceiling value of $1,344.52 and is a firm fixed-price delivery order with a final completion date of November 8, 2024. The contract is not designated with any set-aside requirements, indicating open competition. Amerisourcebergen Drug Corp holds a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,759.12, is for the supply of NAYZILAM 5 MG NASAL SPRAYS to support federal government healthcare programs. The contract is a firm fixed-price delivery order, with an ultimate completion date of December 27, 2024. It is not designated as a set-aside contract, indicating open competition....
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,464.07 firm-fixed-price delivery order is for the supply of NAYZILAM 5 MG NASAL SPRAYS, a medication used for the treatment of seizures. The contract has an ultimate completion date of December 11, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,410.34 firm fixed-price delivery order is for the supply of NAYZILAM 5 MG NASAL SPRAYS. This order is part of AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for...
  • SPE2DB24D2205
    Indefinite Delivery Contract
  • SPE2DB24D2205-SPE2DB25FDZXA
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of NAYZILAM 5 MG NASAL SPRAYS, with a ceiling value of $2,086.50 and a period of performance through March 21, 2025.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

The contract award was not designated with a set-aside requirement, indicating open competition.

Generated 6/19/25, 9:51 AM